Veterinary Drug terms — page 14 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Methoxsalen 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; methoxsalen; 8-Methoxypsoralen; 298-81-7; XANTHOTOXIN; Meladinine; Ammoidin; Xanthotoxine; 8-MOP; Meloxine; Oxsoralen; Meladinin; Oxypsoralen; Puvalen; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; Meladoxen; Ammodin; Uvadex; Methoxa-Dome; 8-Methoxypsoralene; Oxsoralen-ultra; New-Meladinin; Geroxalen; Methoxalen; Puvamet; Oxsoralen lotion; Zanthotoxin; Oxsoralen Ultra; Psoralon-MOP; 9-Methoxypsoralen; 8-MP; 8-Methoxyfuranocoumarin; 9-methoxyfuro[3,2-g]chromen-7-one; Proralone-mop; O-methylxanthotoxol; Meladinin (VAN); 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 8-Methoxy-2',3',6,7-furocoumarin; NCI-C55903; 7H-Furo[3,2-g][1]benzopyran-7-one, 9-methoxy-; Methoxy-8-psoralen; 8-Methoxy-4',5',6,7-furocoumarin; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; UNII-U4VJ29L7BQ; 8-Methoxy-[furano-3'.2':6.7-coumarin]; NSC45923; NSC 45923; 8-Methoxy-4',5':6,7-furocoumarin; CCRIS 2083; HSDB 2505; 8-Methoxy-(furano-3'.2':6.7-coumarin); 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 8-Methoxypsoralen with ultraviolet A therapy; Methoxsalen (Oxsoralen); EINECS 206-066-9; MFCD00005009; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; Methoxsalen plus ultraviolet radiation; CHEMBL416; 7H-Furo(3,2-G)(1)benzopyran-7-one, 9-methoxy-; BRN 0196453; U4VJ29L7BQ; 8-Methoxy-6,7-furanocoumarin; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; CHEBI:18358; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; QXKHYNVANLEOEG-UHFFFAOYSA-N; NSC-45923; 9-methoxyfurano[3,2-g]chromen-2-one; NCGC00016418-07; AK111265; CAS-298-81-7; Methoxaten; Oxoralen; ST041029; Psoralen-mop; DSSTox_CID_830; 8-Methoxypsoralen, 99%; EN300-52504; Ultra Mop; DSSTox_RID_75816; DSSTox_GSID_20830; Q-100381; Deltapsoralen; Dltasoralen; Methoxsalene; Metoxaleno; Methoxsalen [BAN:JAN]; 7-Furocoumarin; Oxsoralen Ul tra; 8-Methoxy; Methoxsalen, 8-; CPD000071170; SMR000071170; OXSORALEN (TN); SR-01000629727; Vitpso; Methoxsalen [USP:BAN:JAN]; Prestwick_661; Methoxsalen with ultra-violet A theraphy; Spectrum_001023; 5-Demethoxyisoimpinellin; 8-Methoxy(furano-3'.2':6.7-coumarin); Prestwick0_000479; Prestwick1_000479; Prestwick2_000479; Prestwick3_000479; Spectrum2_001052; Spectrum3_000499; Spectrum4_000052; Spectrum5_001891; UVADEX (TN); 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; Methoxsalen (JP17/USP); 7H-Furo[3, 9-methoxy-; Oprea1_166319; SCHEMBL19168; BSPBio_000618; BSPBio_001997; KBioGR_000543; KBioSS_001503; 5-19-06-00015 (Beilstein Handbook Reference); 8MO; MLS000062633; MLS002303011; DivK1c_000763; SPECTRUM1500400; SPBio_001004; SPBio_002557; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); BPBio1_000680; MEGxp0_000095; Xanthotoxin, analytical standard; DTXSID8020830; ACon1_000174; HMS502G05; KBio1_000763; KBio2_001503; KBio2_004071; KBio2_006639; KBio3_001497; 8-Methoxy-2',6,7-furocoumarin; 8-Methoxy-4',6,7-furocoumarin; NINDS_000763; HMS1569O20; HMS1920N05; HMS2091D20; HMS2096O20; HMS2269P03; HMS3259L13; HMS3655B05; LS-68; Pharmakon1600-01500400; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; BCP28212; SM-88 COMPONENT METHOXSALEN; ZINC2548959; Tox21_110432; Tox21_201767; Tox21_302816; 8-Methoxypsoralen; Xanthotoxin; 8-MOP; BDBM50041234; BG0479; CCG-36366; CM-131; GP5578; NSC757114; s1952; SBB005950; STK735539; WLN: T C566 DO LVOJ BO1; 8-Methoxypsoralen, analytical standard; AKOS000277012; Tox21_110432_1; 9-Methoxy-furo[3,2-g]chromen-7-one; AC-4259; AM84906; API0008254; CS-1983; DB00553; DS-5159; MCULE-2500932325; NC00652; NSC-757114; SDCCGMLS-0042377.P002; IDI1_000763; KS-00000J91; 8-methoxy-2'',3'',6,7-furocoumarin; 8-methoxy-4'',5'':6,7-furocoumarin; NCGC00016418-01; NCGC00016418-02; NCGC00016418-03; NCGC00016418-04; NCGC00016418-05; NCGC00016418-06; NCGC00016418-08; NCGC00016418-09; NCGC00016418-10; NCGC00016418-11; NCGC00016418-12; NCGC00016418-14; NCGC00016418-15; NCGC00060938-02; NCGC00060938-03; NCGC00060938-04; NCGC00060938-05; NCGC00060938-06; NCGC00178871-01; NCGC00178871-02; NCGC00178871-03; NCGC00256435-01; NCGC00259316-01; 4CN-0934; CC-30277; HY-30151; NCI60_004085; Q039; SAM002548974; SAM002564221; SC-13812; SBI-0051443.P003; AB2000388; AX8020056; BC4157549; FT-0082222; FT-0602101; N1305; ST24045871; SW167762-4; 8-methoxy-[furano-3''.2'':6.7-coumarin]; 9-Methoxy-7H-furo[3,2-g]chromen-7-one #; C01864; D00139; J10204; AB00052042-14; AB00052042-15; AB00052042_16; AB00052042_17; 298M817; 9-METHOXY-2H-FURO[3,2-G]CHROMEN-2-ONE; 9-Methoxy-7H-furo[3,2- g][1]benzopyran-7-one; C-11618; Q408570; SR-01000629727-2; SR-01000629727-4; BRD-K63430059-001-03-2; BRD-K63430059-001-06-5; BRD-K63430059-001-09-9; Z1258578369; Xanthotoxin; Metoxaleno; Dltasoralen; Meladinine; Uvadex,; Oxsoralen; Methoxsalen, United States Pharmacopeia (USP) Reference Standard; Methoxsalen; 5-19-06-00015 (Beilstein Handbook Reference)
Methoxyflurane 2,2-Dichloro-1,1-difluoro-1-methoxyethane; methoxyflurane; 76-38-0; Methoxyfluran; Methoflurane; Penthrane; Metoxifluran; Metoxfluran; Methoxane; Anecotan; Metofane; Pentrane; 2,2-Dichloro-1,1-difluoroethyl methyl ether; Analgizer; Methofane; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; Inhalan; Pentran; Methoxifluranum; Ingalan; Methoxiflurane; Methoxyfluoran; Metossiflurano [DCIT]; Methoxyfluranum; Metoxiflurano; Ethane, 2,2-dichloro-1,1-difluoro-1-methoxy-; Methoxyfluranum [INN-Latin]; Metoxiflurano [INN-Spanish]; Penthrane (VAN); Metofane (VAN); NSC-110432; Methyl 1,1-difluoro-2,2-dichloroethyl ether; C3H4Cl2F2O; (2,2-dichloro-1,1-difluoroethyl) methyl ether; CCRIS 5840; UNII-30905R8O7B; HSDB 7201; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; EINECS 200-956-0; Methoxyflurane [Anaesthetics, volatile]; BRN 1737766; CHEBI:6843; RFKMCNOHBTXSMU-UHFFFAOYSA-N; 2,2-DICHLORO-1,1-DIFLUOROETHYLMETHYLETHER; DA-759; 30905R8O7B; NCGC00168747-01; Methofluranum; Metossiflurano; Penthrane (TN); Methoxyflurane [USAN:INN:BAN]; Methoxyflurane (USP/INN); Methoxy flurane; Methoxyflurane [USAN:USP:INN:BAN]; WLN: GYGXFFO1; DSSTox_CID_5556; CHEMBL1341; DSSTox_RID_77827; DSSTox_GSID_25556; SCHEMBL121229; 2,1-difluoro-1-methoxyethane; 2,1-difluoroethyl methyl ether; GTPL7234; DTXSID7025556; CTK3J6922; ZINC896988; HY-B0718; ZX-AP002154; Tox21_112626; 9405AE; FCH917967; MFCD00040144; NSC110432; PC9601; SBB087860; AKOS006228995; DB01028; KS-5167; LS-1693; MCULE-6052691210; RTR-024462; CAS-76-38-0; CC-06443; Ether,2-dichloro-1,1-difluoroethyl methyl; DB-019611; TR-024462; CS-0009624; Ethane,2-dichloro-1,1-difluoro-1-methoxy-; FT-0628312; ST51041742; C-5420; C07517; D00544; C-04551; Q411594; SR-01000944693; SR-01000944693-1; Methoxyflurane; 4-02-00-00503 (Beilstein Handbook Reference)
Methyl 3-hydroxybenzoate 3-Hydroxybenzoic acid, Methyl ester; Methyl 3-hydroxybenzoate; AI3-31869
Methyl isocyanate Isocyanatomethane; METHYL ISOCYANATE; Isocyanatomethane; Methane, isocyanato-; 624-83-9; Methyl carbonimide; methylisocyanate; Methylcarbylamine; Isocyanate de methyle; Iso-cyanatomethane; Methylisocyanaat; (Methylimino)(oxo)methane; Methyl isocyanat; Metil isocianato; Isocyanic acid, methyl ester; Methylisokyanat; methylimino(oxo)methane; RCRA waste number P064; Isocyanate, methyl-; Methylisokyanat [Czech]; Methylisocyanaat [Dutch]; Methyl isocyanat [German]; Metil isocianato [Italian]; UNII-C588JJ4BV9; NSC 64323; TL 1450; UN 2480; CCRIS 1385; Isocyanate de methyle [French]; CHEBI:59059; HSDB 1165; CH3NCO; EINECS 210-866-3; UN2480; RCRA waste no. P064; BRN 0605318; AI3-28280; C588JJ4BV9; HAMGRBXTJNITHG-UHFFFAOYSA-N; 30108-95-3; MIC [Isocyanate]; Poly(methylisocyanate); Methylisocyanate polymer; MP-NCO; Methyl isocyanat [German]; Methyl isocynate; Methyl-isocyanate; MeNCO; methylimino-oxomethane; Me-NCO; isocyanate polymer bound; METHYLISOCYANATE 1 X 500MG NEAT; DSSTox_CID_3786; C2H3NO; Epitope ID:122968; WLN: OCN1; methane, (methylimino)oxo-; DSSTox_RID_77191; DSSTox_GSID_23786; (Methylimino)(oxo)methane #; 4-04-00-00247 (Beilstein Handbook Reference); GTPL6290; methylimino(oxidanylidene)methane; CHEMBL1608558; DTXSID1023786; CTK2F3714; Methane, isocyanato-, homopolymer; ALBB-007556; KS-000025XS; NSC64323; ZINC8681666; ZX-AN007078; Tox21_201060; NSC-64323; STK504617; Isocyanicacid, methyl ester, polymers; AKOS005171723; DB12765; GS-3554; LS-1498; MCULE-7764606582; Methyl isocyanate [UN2480] [Poison]; Methyl isocyanate [UN2480] [Poison]; NCGC00091082-01; NCGC00091082-02; NCGC00258613-01; CAS-624-83-9; InChI=1/C2H3NO/c1-3-2-4/h1H; TR-021487; BB 0253944; FT-0679344; 51444-EP2275425A1; 51444-EP2277880A1; 51444-EP2292606A1; 51444-EP2292610A1; 51444-EP2308861A1; 51444-EP2311824A1; 624M839; A833804; Q410431; Isocyanate, polymer-bound, 200-400 mesh, extent of labeling: 1.5-2.5 mmol/g loading, 2 % cross-linked with divinylbenzene; Methyl isocyanate bound to polystyrene HL, extent of labeling: ~1.6 mmol/g isocyanate loading (high loading); ScavengePore(TM) benzyl isocyanate, macroporous, 40-70 mesh, extent of labeling: 0.5-2.0 mmol/g loading; StratoSpheres(TM) PL-NCO (Isocyanate) resin, 150-300 mum, extent of labeling: >=1.5 mmol/g loading, 1 % cross-linked; Methyl isocyanate; 4-04-00-00247 (Beilstein Handbook Reference)
Methyl isocyanide Isocyano-methane; Methylisonitrile; EINECS 209-806-9
Methyl red 2-[[4-(Dimethylamino)phenyl]azo]benzoic acid; Methyl red; C.I. 13020
Methyl trans-cinnamate Methyl (2E)-3-phenylprop-2-enoate; Methyl trans-cinnamate; Methyl trans-cinnamate
Methylamine Methanamine; METHYLAMINE; Methanamine; Aminomethane; Monomethylamine; 74-89-5; Carbinamine; Mercurialin; N-Methylamine; Methylaminen; Metilamine; Metyloamina; monomethyl amine; Anhydrous Methylamine; Methylamine aq; Methylamine solutions; Methylaminen [Dutch]; Metilamine [Italian]; Metyloamina [Polish]; methyl-amine; UNII-BSF23SJ79E; CCRIS 2508; HSDB 810; MeNH2; Methylamine, anhydrous; EINECS 200-820-0; UN1061; UN1235; CH3NH2; AI3-15637-X; BSF23SJ79E; Methylamine, in aqueous solution; CHEBI:16830; BAVYZALUXZFZLV-UHFFFAOYSA-N; Methylamine solution (42% or less); NME; methylamin; methyl amine; methaneamine; methlamine; methlyamine; methyamine; methylammonia; methylarnine; metylamine; methyl group; methylamine-; mono-methylamine; N-methyl amine; mono methyl amine; mono-methyl amine; Methylamine solution; Methylamine anhydrous; Aminomethylidyneradical; H2NMe; NH2Me; ACMC-1BEIQ; DEA Code 8520; H2NCH3; NH2CH3; EC 200-820-0; Methylamine aqueous solution; Methylamine, >=99.0%; CH3-NH2; Methylamine, aqueous solution; Integrase inhibitor, R3{3}; KSC377M9L; UN 1235 (Salt/Mix); CHEMBL43280; Methylamine, purum, >99.5%; DTXSID7025683; Methylamine, solution in ethanol; CTK2H7695; Methylamine, anhydrous, >=98%; Methylamine, purum, >=99.0%; Methyl Of Gamma-N-Methylasparagine; KS-00000UF8; STR00032; BDBM50416492; BP-11399B; MFCD00008104; STL281863; Methylamine solution, 2.0 M in THF; AKOS009031510; InChI=1/CH5N/c1-2/h2H2,1H; DB01828; LS-1634; MCULE-1379281060; RTR-037660; TRA0074535; UN 1061; Methylamine solution, 2.0 M in methanol; Methylamine solution, 40 wt. % in H2O; SC-46830; TR-037660; FT-0628859; M0137; M1016; M2108; M2323; M2324; A23960; C00218; Methylamine, anhydrous [UN1061] [Flammable gas]; Q409304; Methylamine solution, 33 wt. % in absolute ethanol; Methylamine, anhydrous [UN1061] [Flammable gas]; Methylamine, aqueous solution [UN1235] [Flammable liquid]; Methylamine, aqueous solution [UN1235] [Flammable liquid]; Polystyrene AM-NH2, macrobeads, extent of labeling: 0.8-1.4 mmol/g N loading; 3P8; JandaJel(TM)-NH2, 100-200 mesh, extent of labeling: 1.0 mmol/g N loading, 2 % cross-linked; JandaJel(TM)-NH2, 200-400 mesh, extent of labeling: 1.0 mmol/g N loading, 2 % cross-linked; JandaJel(TM)-NH2, 50-100 mesh, extent of labeling: 1.0 mmol/g N loading, 2 % cross-linked; MEN; Methylamine; AI3-15637-X
Methylene dithiocyanate Thiocyanic acid, C,C'-Methylene ester; Methylene bis(thiocyanate); V 709
Methylglyoxal 2-Oxopropanal; methylglyoxal; pyruvaldehyde; 2-Oxopropanal; pyruvic aldehyde; acetylformaldehyde; 78-98-8; Propanal, 2-oxo-; Acetylformyl; Propanedione; 2-Ketopropionaldehyde; METHYL GLYOXAL; Propanolone; Pyroracemic aldehyde; 2-Oxopropionaldehyde; Glyoxal, methyl; alpha-Ketopropionaldehyde; 1-Ketopropionaldehyde; Propionaldehyde, 2-keto; Propionaldehyde, 2-oxo-; 1,2-Propanedione; Acetalformaldehyde; alpha-Ketopropionic aldehyde; 2-oxo-Propionaldehyde; CH3COCHO; FEMA No. 2969; CCRIS 1741; methyl-glyoxal; 2-oxo-propanal; NSC 79019; NSC 626580; Methylglyoxal solution; UNII-722KLD7415; CHEBI:17158; EINECS 201-164-8; MFCD00006960; .alpha.-Ketopropionaldehyde; NSC 337790; BRN 0906750; AIJULSRZWUXGPQ-UHFFFAOYSA-N; Pyruvaldehyde polymer; NSC626580; 722KLD7415; oxopropanal; Pyruvic aldehyde, 35-45 wt% solution in water; Ethanol Ketone; HSDB 7510; Ketopropionaldehyde; acetyl formaldehyde; 51252-84-7; Pyruvaldehyde solution; Pyruvaldehyde (8CI); 2-keto Propionaldehyde; DSSTox_CID_1628; Epitope ID:143620; WLN: VHV1; EC 201-164-8; DSSTox_GSID_21628; 4-01-00-03631 (Beilstein Handbook Reference); KSC377C2D; Propanal, 2-oxo- (9CI); Pyruvaldehyde, 40% in water; CHEMBL170721; GTPL6303; DTXSID0021628; CTK2H7121; Pyruvic Aldehyde (40% solution); NSC79019; STR03080; ZINC1532681; Tox21_303931; ANW-37250; KM1949; Methylglyoxal solution 40% in water; NSC-79019; NSC133492; NSC133493; AKOS000119318; AB00820; DB03587; HY-W020014; MCULE-2718961814; Methylglyoxal solution, ~40% in H2O; NSC-133492; NSC-133493; NSC-626580; RTR-025193; CAS-78-98-8; KS-0000006N; NCGC00356972-01; BP-20618; H451; SC-74380; LS-139762; Pyruvaldehyde solution, 40 wt. % in H2O; CS-0031856; FT-0646558; C00546; Methylglyoxal solution, technical, ~40% in H2O; Q903881; 194597AC-5BFC-42EA-B6C8-DA2E5FAA13AF; J-510228; F0001-2060; Pyruvaldehyde; 4-01-00-03631 (Beilstein Handbook Reference)
Methyltestosterone (17beta)-17-Hydroxy-17-methylandrost-4-en-3-one; methyltestosterone; 17-Methyltestosterone; 58-18-4; Testred; Metandren; Android; 17alpha-Methyltestosterone; Androsan; Androsten; Mesterone; Virilon; Malestrone; Mastestona; Synandrets; Synandrotabs; Testhormone; Andrometh; Anertan; Dumogran; Homandren; Hormale; Malogen; Masenone; Metestone; Metrone; Nabolin; Oraviron; Steronyl; Syndren; Testora; Oreton Methyl; Glosso-sterandryl; Oreton-M; M.T.Mucorettes; Neo-Hombreol-M; Nu-man; Android 5; Android 10; Android 25; Methitest; Orchisterone-M; Testovis Depot; Homandren, tablets; NSC-9701; Estratest; Metiltestosterona; Glosso sterandryl; Methyltestosteronum; Anertan (tablets); Homandren (VAN); Testovis (tablet); 17beta-Hydroxy-17-methylandrost-4-en-3-one; Androsan (tablets); Androsan (VAN); Testoviron (VAN); Anertan (VAN); Testoviron (tablet); 17-Methyltestosteron; CDB 110; Metiltestosterone [DCIT]; UNII-V9EFU16ZIF; RU 24400; Anertan, tablets; 17-Hydroxy-17-methyl-3-keto-androstene-4; 17alpha-Methyl-3-oxo-4-androsten-17beta-ol; 17-beta-Hydroxy-17-methylandrost-4-en-3-one; 4-Androstene-17alpha-methyl-17beta-ol-3-one; CCRIS 3723; Methyltestosteronum [INN-Latin]; Metiltestosterona [INN-Spanish]; HSDB 3365; 17|A-Methyltestosterone; EINECS 200-366-3; METHYL TESTOSTERONE; U 2842; V9EFU16ZIF; 17alpha-Methyl-delta-androsten-17beta-ol-3-one; NSC 139965; BRN 2057425; L 589.372; Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17beta)-; Premarin with methyltestosterone; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; CHEBI:27436; Oreton M; Androsan, tablets; GCKMFJBGXUYNAG-HLXURNFRSA-N; component of Estan; 4-Androstene-17-alpha-methyl-17-beta-ol-3-one; Androst-4-en-3-one, 17beta-hydroxy-17-methyl-; (17beta)-17-hydroxy-17-methylandrost-4-en-3-one; Neo-Hombreol [M]; (17-beta)-17-Hydroxy-17-methylandrost-4-en-3-one; Neo-Homobreol (M); Neo-Homobreol [M]; component of Gynetone; 17(alpha)-Methyl-delta4-androsten-17(beta)-ol-3-one; NSC-139965; Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17b)-; NCGC00091009-03; component of Tylosterone; Testosterone, 17-methyl-; DSSTox_CID_13664; DSSTox_RID_79089; DSSTox_GSID_33664; 17.alpha.-Methyltestosterone; 17.alpha.-Methyl-3-oxo-4-androsten-17.beta.-ol; Androst-4-en-3-one, 17-beta-hydroxy-17-methyl-; 4-Androstene-17.alpha.-methyl-17.beta.-ol-3-one; Androst-4-en-3-one, 17.beta.-hydroxy-17-methyl-; Mesteron; Oretron; Metiltestosterone; Estan (Salt/Mix); Estratest HS; Android-5; CAS-58-18-4; Estratest (Salt/Mix); Estratest H.S.; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; SMR000058528; Android (TN); Android-10; Android-25; 17beta-Methyltestosterone; WLN: L E5 B666 OV MUTJ A E FQ F -B&AEF; 17 beta-Methyltestosterone; 17-alpha-Methyltestosterone; component of Gynetone (Salt/Mix); Estratest-HS; NCGC00091009-04; NCGC00091009-05; Testred (TN); Premarin with Methyltestosterone (Salt/Mix); 17-Hydroxy-17-methylandrost-4-en-3-one #; Methyltestosterone ciii; Methyltestosterone [USP:INN:BAN:JAN]; Conjugated estrogens / methyltestosterone; Methyltestosterone [USAN:INN:BAN:JAN]; 17-.beta.-Hydroxy-17-methylandrost-4-en-3-one; Androst-4-en-3-on-17.beta.-ol, 17.alpha.-methyl; Androst-4-ene-17.alpha.-methyl-17.beta.-ol-3-one; 17beta-Hydroxy-17-methyl-4-androsten-3-one; 17 beta-Hydroxy-17-methyl-4-androsten-3-one; 17.beta.-Hydroxy-17.alpha.-methylandrost-4-en-3-one; 17.alpha.-methyl-.DELTA.4-androsten-17.beta.-ol-3-one; CHEMBL1395; SCHEMBL18657; 4-08-00-01010 (Beilstein Handbook Reference); Conjugated estrogens mixture with methyltestosterone; Methyltestosterone mixture with conjugated estrogens; MLS000759474; MLS001424040; MLS002174282; GTPL6945; DTXSID1033664; CDB-110; NSC9701; 17-MT; HMS2051A14; HMS2272A06; HY-A0121; ZINC3814422; Tox21_113161; Tox21_113162; Tox21_400058; BDBM50410531; LMST02020029; Methyltestosterone (JP17/USP/INN); NSC139965; AKOS015917317; Tox21_113162_1; ACN-031982; API0003346; CCG-100871; CS-5099; DB06710; GS-6594; MCULE-5274452426; NC00121; NCGC00091009-01; NCGC00091009-06; NCGC00091009-07; 262423-02-9; LS-19506; RU-24400; SC-16208; SMR001261452; M0435; 17alpha-Methyltestosterone, >=97.0% (HPLC); C07198; D00408; Methyltestosterone (17alpha-Methyltestosterone); U-2842; AB00443683-06; AB00443683-09; 17alpha-methyl-Delta4-androsten-17beta-ol-3-one; 17alpha-Methyltestosterone, solid (photosensitive); 17beta-Hydroxy-17alpha-methyl-4-androsten-3-one; Q421768; 17alpha-methyl-Delta(4)-androsten-17beta-ol-3-one; L-589372; L-589.372; 17-alpha-Methyltestosterone 100 microg/mL in Methanol; 17(alpha)-methyl-Delta(4)-androsten-17(beta)-ol-3-one; 17-alpha-Methyltestosterone 100 microg/mL in Acetonitrile; 17alpha-Methyltestosterone, VETRANAL(TM), analytical standard; Methyltestosterone, European Pharmacopoeia (EP) Reference Standard; Methyltestosterone (17alpha-Methyltestosterone) 1.0 mg/ml in Acetonitrile; Methyltestosterone, United States Pharmacopeia (USP) Reference Standard; Methyltestosterone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0(2),.0(1)(1),(1)]heptadec-6-en-5-one; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one; (8R,10R,13S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one; 17alpha-Methyltestosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, ampule of 1 mL, certified reference material; Methyltestosterone aka ''(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; Methyltestosterone; 4-08-00-01010 (Beilstein Handbook Reference)
Methyltrienolone (17beta)-17-Hydroxy-17-methylestra-4,9,11-trien-3-one; Methyltrienolone; METRIBOLONE; 965-93-5; R1881; 17alpha-Methyltrienolone; MetriboloMetribolonum; RU 1881; 17-beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; R 1881; UNII-2C323EGI97; 17beta-Hydroxy-17-methylestra-4,9,11-trien-3-one; R-1881; (17BETA)-17-HYDROXY-17-METHYLESTRA-4,9,11-TRIEN-3-ONE; R1881 (synthetic androgen); CHEBI:379896; 2C323EGI97; Estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17b)-; 17-methyloestra-4,9,11-trien-3-one,17beta-ol; 17-beta-hydroxy-17-methylestra-4,9,11-trien-3-one (9CI); Estra-4,9,11-trien-3-one, 17beta-hydroxy-17-methyl- (8CI); Estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17beta)- (9CI); Ru-1881; (8S,13S,14S,17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; [3H]methyltrienolone; MLS002695156; Metribolone [INN:DCF]; Metribolonum [INN-Latin]; Metribolona [INN-Spanish]; Methyl trienolone; 1xow; NSC 92858; 1e3g; 2ao6; [3H]R1881; [3H]-R1881; 17.alpha.-Methyltrienolone; 17-.alpha.-Methyltrienolone; SCHEMBL114862; CHEMBL166444; GTPL2857; GTPL3457; DTXSID8034162; estra-4,9,11-trien-3-one, 17-hydroxy-17-methyl-, (17beta)-; NSC92858; ZINC3814420; BDBM50367916; NSC-92858; AKOS015840270; AB04711; DB02998; SC-16235; R1881, >=98% (HPLC); C14257; 965M935; Q3333717; 17-.beta.-Hydroxy-17-methylestra-4,11-trien-3-one; 17alpha-Methyl-3-oxo-4,9,11-estratrien-17beta-ol; 17alpha-methyl-4,9,11,estratrien-17beta-ol-3-one; 3-Oxo-17beta-hydroxy-17-methylestra-4,9,11-triene; 17alpha-Methyl-17beta-hydroxyestr-4,9,11-trien-3-one; 17alpha-Methyl-17beta-hydroxyestra-4,9,11-trien-3-one; Estra-4,11-trien-3-one, 17.beta.-hydroxy-17-methyl-; 17alpha-methyl-17beta-hydroxy-estra-4,9,11-trien-3-one; 3-Oxo-17beta-hydroxy-17alpha-methylestra-4,9,11-triene; (17beta)-17-hydroxy-17-methyl-estra-4,9,11-triene-3-one; 17alpha-Methyl-17beta-hydroxyestra-4,9(10),11-trien-3-one; 17-beta-hydroxy-17-methyl-19-norandrosta-4,9,11-triene-3-one; Estra-4,11-trien-3-one, 17-hydroxy-17-methyl-, (17.beta.)-; Estra-4,9,11-trien-3-one, 17beta-hydroxy-17-methyl- (7CI,8CI); METHYLTRIENOLONE; 17BETA-HYDROXY-17METHYL-19NORANDROSTA-4,9,11-TRIEN-3-ONE; R1881; Metribolone; R 1881
Methysergide (8beta)-9,10-Didehydro-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethylergoline-8-carboxamide; Methysergide; BRN 0765985
Metoprolol 1-[4-(2-Methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol; metoprolol; 51384-51-1; (RS)-Metoprolol; Spesicor; Beatrolol; Toprol; dl-Metoprolol; 37350-58-6; Meijoprolol; Metoprololum; Metohexal; Preblok; Presolol; Seroken; Lopressor; Spesikor; Betalok; Metoprolol succinate; TOPROL-XL; CGP 2175; Metoprololum [INN-Latin]; 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol; Metoprolol [USAN:INN:BAN]; 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; CGP-2175; LOPRESSIDONE; CCRIS 4198; HSDB 6531; CHEMBL13; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; 1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol; CHEBI:6904; IUBSYMUCCVWXPE-UHFFFAOYSA-N; Selo-Zok; Lopresoretic; 1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol; Beloc-Duriles; Betaloc-Astra; 2-Propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-; 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-; Loresor; Neobloc; Metrol; {2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl}(propan-2-yl)amine; 1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol; 2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (.+/-.)-; CGP-2175C; CGP2175; Metoprolol (USAN/INN); 1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanol; H-93/26; 1-(4-(2-Methoxyethyl)-phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-[4-(2-METHOXYETHYL)-PHENOXY]-3-[(1-METHYLETHYL)AMINO]-2-PROPANOL; metoprolol tartarate; H 93-26; EINECS 253-483-7; EINECS 257-166-4; (+/-)-Metoprolol; Lopresol (Salt/Mix); Lopresoretic (Salt/Mix); (.+/-.)-Metoprolol; 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol; DSSTox_CID_3309; SCHEMBL4093; DSSTox_GSID_23309; GTPL553; 1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]-2-propanol; H 93/26 (Salt/Mix); DTXSID2023309; BDBM25756; CTK7B2896; HMS2090B15; BCP09038; GP-2175E; KS-000022ZD; Tox21_303972; 4761AB; s5430; STL301858; AKOS005927923; BG-0006; CCG-204813; CS-3159; DB00264; MCULE-7999715986; SDCCGSBI-0050706.P005; 2-Propanol, 1-(4-(2-methoxyethyl)phenoxy)-3-((1-methylethyl)amino)-, (+-)-; NCGC00021148-03; NCGC00021148-04; NCGC00021148-05; NCGC00356981-01; AC-19022; H929; HY-17503; SBI-0050706.P004; AB0013365; CAS-51384-51-1; DB-049097; LS-122450; ST2407314; A2878; AB00053499; FT-0602794; FT-0654603; C07202; D02358; X-3755; AB00053499-21; AB00053499_22; AB00053499_23; A823609; L000669; Q409468; Q-201400; SR-01000003148-2; BRD-A03623303-045-02-0; BRD-A03623303-045-05-3; 1-Isopropylamino-3-[p-(2-methoxyethyl)phenoxy]-2-propanol; 1-[4-(2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol; (+/-)-1-(Isopropylamino)-3-(p-(beta-methoxyethyl)phenoxy)-2-propanol; (2S)-1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2R,3R)-2,3-dihydroxysuccinic acid; 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol; Metoprolol; EINECS 257-166-4
Metronidazole 2-Methyl-5-nitro-1H-imidazole-1-ethanol; Metronidazole; 5-23-05-00063 (Beilstein Handbook Reference)
Metyrapone 2-Methyl-1,2-di-3-pyridinyl-1-propanone; metyrapone; 54-36-4; 2-Methyl-1,2-di-3-pyridyl-1-propanone; Metopirone; Methopyrapone; Metopiron; Methapyrapone; Methopirapone; Methopyrinine; Methopyrone; Metyrapon; Methbipyranone; Metopyrone; Mepyrapone; Metroprione; Metapirone; Metapyron; Metirapona; Metyraponum; Su 4885; 1-Propanone, 2-methyl-1,2-di-3-pyridinyl-; 2-methyl-1,2-dipyridin-3-ylpropan-1-one; Metyraponum [INN-Latin]; Metirapona [INN-Spanish]; 2-Methyl-1,2-di-3-pyridinyl-1-propanone; UNII-ZS9KD92H6V; 2-Methyl-1,2-bis(3-pyridyl)-1-propanone; NSC 25265; 1,2-Di-3-pyridyl-2-methyl-1-propanone; HSDB 2500; 1-Propanone, 2-methyl-1,2-di-3-pyridyl-; EINECS 200-206-2; NSC-25265; CHEMBL934; ZS9KD92H6V; 1-Propanone, 1,2-di-3-pyridyl-2-methyl-; 2-methyl-1,2-dipyridin-3-yl-propan-1-one; CHEBI:44241; 2-methyl-1,2-bis(pyridin-3-yl)propan-1-one; FJLBFSROUSIWMA-UHFFFAOYSA-N; CAS-54-36-4; NCGC00016242-01; DSSTox_CID_3314; 2-methyl-1,2-di(pyridin-3-yl)propan-1-one; DSSTox_RID_76971; DSSTox_GSID_23314; MYT; SMR000059134; Metyrapone [USAN:INN:BAN:JAN]; METOPIRONE (TN); Metyrapone [USAN:USP:INN:BAN:JAN]; PubChem16052; Prestwick0_000904; Prestwick1_000904; Prestwick2_000904; Prestwick3_000904; BIDD:PXR0082; BSPBio_000748; MLS001066377; MLS001335881; MLS001335882; SCHEMBL637432; SPBio_002947; 1-Propanone,2-di-3-pyridyl-; BPBio1_000824; GTPL5224; Metyrapone (JP17/USP/INN); ZINC1728; DTXSID1023314; 1-Propanone,2-di-3-pyridinyl-; CTK8B5187; KS-00001FBF; HMS1570F10; HMS2094I07; HMS2097F10; HMS2235E16; HMS3259O05; HMS3371B16; HMS3714F10; HMS3742E21; Pharmakon1600-01506014; BCP19099; EX-A1403; HY-B1232; NSC25265; Tox21_110323; ANW-47874; BDBM50028166; BG0427; MFCD00006397; NSC760076; s5416; AKOS015919707; Metyrapone, >=98% (HPLC), solid; Tox21_110323_1; API0003315; CCG-213598; CS-4879; DB01011; MCULE-7018205003; NC00462; NSC-760076; NCGC00016242-02; NCGC00016242-03; NCGC00016242-05; NCGC00161837-01; AK-51541; AS-56195; BR-51541; CC-30940; CPD000059134; SAM002297829; SC-49180; 2-methyl-1,2-di(3-pyridyl)propan-1-one; AX8140081; DB-052546; LS-123097; TC-136619; 2-methyl-1,2-bis(3-pyridinyl)-1-propanone; AB00513955; B7347; EU-0009322; FT-0603230; ST24028079; ST51006925; W6860; Su-4885; Su 4885; Su4885; 2-Methyl-1,2-di(3-pyridinyl)-1-propanone #; C07205; D00410; S-6399; 2-Methyl-1,2-di-3-pyridyl-1-propanone, 96%; AB00513955_07; 054M364; A830124; C-12887; Q821641; SR-01000765398; SR-01000765398-2; BRD-K46862739-001-03-6; Metyrapone, United States Pharmacopeia (USP) Reference Standard; Metyrapone; 1,2-Di-3-pyridyl-2-methyl-1-propanone
Mevalonic acid 3,5-Dihydroxy-3-methylpentanoic acid; Mevalonic acid; Mevalonic acid
Mezlocillin (2S,5R,6R)-3,3-Dimethyl-6-[[(2R)-2-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; Mezlocillin; EINECS 257-233-8
Mianserin 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; mianserin; Mianserine; 24219-97-4; Mianseryna [Polish]; MianseriMianserinum; MianseryMianserine [INN-French]; Mianserinum [INN-Latin]; Mianserina [INN-Spanish]; Mianserin [INN:BAN]; Norval; 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; CHEBI:51137; HSDB 7182; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine; EINECS 246-088-6; BRN 0755346; CHEMBL6437; UEQUQVLFIPOEMF-UHFFFAOYSA-N; C18H20N2; Lerivon; 78684-63-6; NCGC00015656-06; DSSTox_CID_3317; DSSTox_RID_76974; DSSTox_GSID_23317; 1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-; Mianserin (INN); CAS-24219-97-4; Tolvon (TN); Mianserin Monohydrochloride; mianserin a; (+-)-Athymil; Spectrum_001810; Prestwick0_000099; Prestwick1_000099; Prestwick2_000099; Prestwick3_000099; Spectrum2_001203; Spectrum3_001836; Spectrum4_001260; Spectrum5_001772; Biomol-NT_000135; Lopac0_000744; Oprea1_703627; SCHEMBL18020; BSPBio_000058; BSPBio_003511; GTPL135; KBioGR_001820; KBioSS_002303; DivK1c_000844; SPBio_000986; SPBio_001997; BPBio1_000064; BPBio1_000331; DTXSID6023317; KBio1_000844; KBio2_002301; KBio2_004869; KBio2_007437; KBio3_003016; NINDS_000844; HMS2089A04; HY-B0188; Tox21_110191; AC-631; BDBM50222218; PDSP1_001532; PDSP2_001516; AKOS005216268; Tox21_110191_1; API0000656; CCG-204829; CS-2078; DB06148; SDCCGSBI-0050722.P004; IDI1_000844; NCGC00015656-04; NCGC00015656-05; NCGC00015656-08; NCGC00015656-09; NCGC00015656-10; NCGC00015656-12; NCGC00024926-03; NCGC00024926-04; 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene; J16.389I; LS-61197; SBI-0050722.P003; AM20041174; FT-0697022; X5019; D08216; L000736; Q416701; BRD-A19661776-001-01-5; BRD-A19661776-003-05-2; BRD-A19661776-003-16-9; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine #; 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8,10,12,15,17-hexaene; Mianserin; BRN 0755346
Midazolam 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; midazolam; Dormicum; 59467-70-8; Buccolam; Versed; Midazolamum; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; Midazolamum [INN-Latin]; Midazolam Base; mezolam; Ro 21-3981; DEA No. 2884; UNII-R60L0SM5BC; USL261; EINECS 261-774-5; CHEMBL655; BRN 0625572; R60L0SM5BC; CHEBI:6931; DDLIGBOFAVUZHB-UHFFFAOYSA-N; C18H13ClFN3; 8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin; 8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine; 4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-; 8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine; HSDB 6751; Dormicum (TN); Midazolam [INN:BAN:JAN]; USL-261; 12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene; NCGC00168254-01; Medazolam; Nayzilam; Midazolam civ; Midazolam [USP:INN:BAN:JAN]; Buccolam (TN); Nayzilam (TN); 08J; Versed (Salt/Mix); Dormonid (Salt/Mix); Hypnovel (Salt/Mix); Flormidal (Salt/Mix); 59467-94-6; Midazolam (JAN/USP/INN); SCHEMBL35061; BIDD:GT0647; Midazolam hydrochloride, solid; GTPL3342; DTXSID5023320; BDBM21363; Midazolam 0.1 mg/ml in Methanol; Midazolam 1.0 mg/ml in Methanol; USL261 (nasal spray formulation); BCP21296; HY-B0676; ZINC95626706; AKOS015842580; ACN-036275; API0003385; CS-2907; DB00683; 4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate; LS-77780; DB-015270; FT-0672402; C07524; D00550; 467M640; Q423071; Midazolam hydrochloride, United States Pharmacopeia (USP) Reference Standard; Midazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),3,5,8,10,12-hexaene; Midazolam; BRN 0625572
Mifepristone (11beta,17beta)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one; (11beta,17beta)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one; (8S,11R,13S,14R,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; CHEBI:94616; ZINC3831129; KS-000002C7; BRD-K44094313-001-01-6; Q27166438; Mifepristone; R 38486
Minocycline (4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide; Minocycline; BRN 3077644
Mitomycin (1aS,8S,8aR,8bS)-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione; Mitomycin C; AI3-26199
Mitotane 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; mitotane; 53-19-0; Mitotan; Lysodren; o,p'-DDD; Chlodithane; Chloditan; Khlodithan; Chlodithan; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 2,4'-Ddd; Mitotano; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; NCI-C04933; Mitotanum [INN-Latin]; o,p'-TDE; 2,4'-Dichlorodiphenyldichloroethane; o,p-Tde; o,p'-Dichlorodiphenyldichloroethane; Mitotano [INN-Spanish]; 2,4'-Dichlorophenyldichlorethane; Benzene, 1-chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; CB313; DDD, o,p'-; CB 313; NSC 38721; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane; C14H10Cl4; CCRIS 4397; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; HSDB 3240; NSC38721; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; EINECS 200-166-6; CB-313; NSC-38721; BRN 2056007; AI3-07575; 1-chloro-4-[2,2-dichloro-1-(2-chlorophenyl)ethyl]benzene; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-; Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-; NCGC00015226-07; Khloditan; Mitotanum; Mytotan; (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; DSSTox_CID_372; ortho,para-DDD; DSSTox_RID_75548; DSSTox_GSID_20372; o,p-DDD; Opeprim; 2,4 -Dichlorodiphenyldichloroethane; Mitotane (Lsodren); Benzene, 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)-, (+-)-; CAS-53-19-0; Lysodren (TN); Mitotane [USAN:INN:JAN]; SMR000326696; SR-01000075751; (o,p)-DDD; Mitotane (JAN/USP/INN); Prestwick_75; Ethane,1-dichloro-; Mitotane (Lysodren); Mitotane [USAN:USP:INN:BAN:JAN]; (2,4'-Dichlorodiphenyl)dichloroethane; PubChem14974; Spectrum_001959; DDD-o,p'; Spectrum2_000916; Spectrum3_000869; Spectrum4_000709; Spectrum5_002060; C 3010; (o,p')-DDD; SCHEMBL4040; CHEMBL1670; Lopac0_000251; WLN: GYGYR BG&R DG; BSPBio_002517; KBioGR_001237; KBioSS_002513; SPECTRUM330082; MLS001335899; MLS001335900; MLS002152914; MLS002153233; DivK1c_000703; SPBio_000792; CHEBI:6954; GTPL6957; Mitotane, >=98% (HPLC); DTXSID9020372; 2,4'-DDD, analytical standard; CTK8E2992; HMS502D05; KBio1_000703; KBio2_002505; KBio2_005073; KBio2_007641; KBio3_002017; JWBOIMRXGHLCPP-UHFFFAOYSA-N; NINDS_000703; HMS1923K19; HMS2091E07; HMS2232C16; HMS3260D04; HMS3369H10; HMS3655G06; HMS3715H07; Pharmakon1600-00330082; BCP11663; 2,4 inverted exclamation marka-DDD; Tox21_110103; Tox21_302804; Tox21_500251; CCG-40014; LS-185; MFCD00000850; NSC755849; s1732; 1,2-bis(2,4'-dichlorophenyl)ethane; AKOS006028802; Tox21_110103_1; CS-1500; DB00648; LP00251; MCULE-2068358149; NSC-755849; SDCCGSBI-0050239.P006; IDI1_000703; 2,4'-DDD 100 microg/mL in Methanol; NCGC00015226-02; NCGC00015226-03; NCGC00015226-04; NCGC00015226-05; NCGC00015226-06; NCGC00015226-08; NCGC00015226-09; NCGC00015226-10; NCGC00015226-11; NCGC00015226-12; NCGC00091374-01; NCGC00091374-02; NCGC00091374-03; NCGC00091374-04; NCGC00091374-05; NCGC00091374-06; NCGC00256452-01; NCGC00260936-01; 2,4'-DDD 10 microg/mL in Cyclohexane; AK546750; AS-11690; HY-13690; NCI60_003688; SC-18530; 2,4'-DDD 100 microg/mL in Cyclohexane; SBI-0050239.P004; AB0010565; TR-018813; EU-0100251; FT-0605518; ST51016017; SW199619-3; EN300-37268; 2,4 inverted exclamation marka-DDD; o,p'-DDD; 2,4'-DDD, PESTANAL(R), analytical standard; D00420; W-5031; AB00052337-09; AB00052337_10; 000M850; Q417465; SR-01000075751-1; SR-01000075751-3; SR-01000075751-6; 2,4'-(2,2-dichloroethane-1,1-diyl)bis(chlorobenzene); Z425389592; 1-(o-Chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane; 1-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-2-chlorobenzene; Ethane,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene #; Mitotane, United States Pharmacopeia (USP) Reference Standard; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8CI); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, analytical standard; o,p'-DDD|||1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane|||Mitotane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane for diagnostic uses (cancer investigation), >=98% (HPLC); 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, for diagnostic uses (cancer investigation), >=98% (HPLC); Mitotane; 4-05-00-01883 (Beilstein Handbook Reference)
Mitoxantrone 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; mitoxantrone; 65271-80-9; Mitozantrone; Mitoxanthrone; DHAQ; Dihydroxyanthraquinone; Mitoxantron; Novantrone; MitoxantroMitoxantronum; Mitoxantronum [INN-Latin]; Mitoxantrona [INN-Spanish]; Mitoxantrone [INN]; NSC 279836; UNII-BZ114NVM5P; DHAD; NSC279836; NSC-279836; Mitoxantrone (INN); CCRIS 7604; 1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone; C22H28N4O6; 1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; BRN 2795126; BZ114NVM5P; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone; 1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione; 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione; MLS002703044; 1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon; CHEBI:50729; KKZJGLLVHKMTCM-UHFFFAOYSA-N; NSC299195; NSC301739; NSC-299195; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-; ANTHRAQUINONE, 5,8-BIS((2-((2-HYDROXYETHYL)AMINO)ETHYL)AMINO)-1,4-DIHYDROXY-; MIX; MLS001333711; Misostol (TN); 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione; NCGC00015693-02; Mitoxantrone (free base); SMR000058480; Mitoxantrone [INN:BAN]; CAS-70476-82-3; DHAQ (*Diacetate salt*); SR-01000076001; 2fum; 1,4-dihydroxy-5,8-bis(2-(2-hydroxyethylamino)ethylamino)anthracene-9,10-dione; 1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthracene-9,10-dione; NSC-301739D; Immunex (Salt/Mix); NSC-287836; Spectrum_001655; Liposome Encapsulated Mitoxantrone (LEM); CHEMBL58; Prestwick0_000385; Prestwick1_000385; Prestwick2_000385; Prestwick3_000385; Spectrum2_000908; Spectrum3_001590; Spectrum4_000866; Spectrum5_001205; Lopac-M-6545; cid_4212; Neuro_000153; SCHEMBL3000; BIDD:PXR0181; Lopac0_000779; BSPBio_000569; BSPBio_003160; KBioGR_001531; KBioSS_002135; AN-584/42007670; DivK1c_000516; SPBio_000756; SPBio_002490; BPBio1_000627; GTPL7242; Novantrone(R) (mitoxantrone for injection concentrate); DTXSID4046947; BDBM67690; cid_5458171; CTK8A5416; KBio1_000516; KBio2_002135; KBio2_004703; KBio2_007271; KBio3_002660; NINDS_000516; HMS2090D05; HMS3655E20; KUC108634N; BCP02861; EBD32557; ZINC3794794; CCG-36371; CM0184; MFCD00242942; s1889; STK631833; Mitoxantrone hydrochloride (Salt/Mix); AKOS005564036; API0003408; BCP9000931; CS-2524; DB01204; KSC-19-204; MCULE-5513787065; SDCCGSBI-0050757.P004; IDI1_000516; SMP2_000179; NCGC00015693-01; NCGC00015693-03; NCGC00015693-04; NCGC00015693-05; NCGC00015693-06; NCGC00015693-08; NCGC00162251-01; AK323601; AS-35321; HY-13502; K061; LS-20638; MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE; NCI60_002276; NCI60_002535; SC-22733; SMR001549953; SY226320; SBI-0050757.P003; TX-017756; AB00053716; FT-0630752; SW196745-6; VU0244399-2; 71M809; C11195; D08224; 13181-EP2270008A1; 13181-EP2270505A1; 13181-EP2272827A1; 13181-EP2275420A1; 13181-EP2277876A1; 13181-EP2289892A1; 13181-EP2292617A1; 13181-EP2295055A2; 13181-EP2295412A1; 13181-EP2295413A1; 13181-EP2295416A2; 13181-EP2295426A1; 13181-EP2295427A1; 13181-EP2298748A2; 13181-EP2298764A1; 13181-EP2298765A1; 13181-EP2301928A1; 13181-EP2305642A2; 13181-EP2305660A1; 13181-EP2311453A1; 13181-EP2311808A1; 13181-EP2311829A1; 13181-EP2311837A1; 13181-EP2311840A1; 13181-EP2311842A2; 13181-EP2316832A1; 13181-EP2316833A1; 13181-EP2316834A1; AB00053716-18; AB00053716-19; AB00053716-22; AB00053716_23; AB00053716_24; Q239426; SR-01000076001-7; BRD-K21680192-001-01-5; BRD-K21680192-001-11-4; BRD-K21680192-300-05-2; BRD-K21680192-300-07-8; BRD-K21680192-300-09-4; BRD-K21680192-300-10-2; BRD-K21680192-300-12-8; 1,4-bis[2-(2-hydroxyethylamino)-ethylamino]-5,8-dihydroxyanthraquinone; 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone; 1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone; 9, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] amino]-; 1,4-Bis[[2-[(2-hydroxyethyl)amino]ethyl]imino]-1,4-dihydroanthracene-5,8,9,10-tetrol; 1,4-Dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-9,10-anthraquinone; hydrochloride; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-anthracene-9,10-dione; 1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; hydrochloride; 1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-bis(oxidanyl)anthracene-9,10-dione; hydrochloride; 1,4-dihydroxy-5,8-bis[2-[(1,1,2,2-tetradeuterio-2-hydroxyethyl)amino]ethylamino]anthracene-9,10-dione; 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI); Mitozantrone|||Novantron|||CL-232325|||1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione; Mitoxantrone; 5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
Mizoribine 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; mizoribine; 50924-49-7; Bredinin; Bredinine; Mizoribine [INN:JAN]; Mizoribinum [INN-Latin]; Mizoribina [INN-Spanish]; HE-69; UNII-4JR41A10VP; MLS000028813; 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide; BRN 4151713; SMR000058473; 4-Carbamoyl-1-beta-D-ribofuranosyl-imidazolium-5-olate; 4JR41A10VP; HE 69; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide; 5-Hydroxy-1-beta-D-ribofuranosylimidazole-4-carboxamide; MZR; NCGC00094087-01; Mizoribinum; Mizoribi1H-Imidazole-4-carboxamide, 5-hydroxy-1-beta-D-ribofuranosyl-; DSSTox_CID_25777; DSSTox_RID_81119; DSSTox_GSID_45777; 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-hydroxy-1H-imidazole-4-carboxamide; Bredinin (TN); 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide; 50524-49-7; CAS-50924-49-7; SR-01000075989; AK162477; Mizoribine(Bredinin); HS-0046; Mizoribine (Bredinin); Opera_ID_1558; Spectrum2_001559; Spectrum3_000739; Spectrum4_000220; Spectrum5_001671; Mizoribine (JP17/INN); M 3047; SCHEMBL7118; Lopac0_000745; BSPBio_002298; KBioGR_000859; MLS001076272; MLS006010038; DivK1c_000948; SPBio_001438; 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olate; CHEMBL245019; cid_104762; Mizoribine, >=98% (TLC); DTXSID8045777; BDBM68669; CHEBI:31858; CTK8G1133; HMS502P10; KBio1_000948; KBio3_001518; KS-00000XHM; N'-(beta-D-Ribofuranosyl)-5-hydroxyimidazole-4-carboxamide; HZQDCMWJEBCWBR-UUOKFMHZSA-N; NINDS_000948; HMS2230D04; HMS3262E12; N'-(beta-D-Ribofuranosyl)-5-hydroxy-imida-zole-4-carboxamide; EX-A2256; ZINC3812887; Tox21_111242; Tox21_500745; CCG-39778; MFCD00057221; QC-367; s1384; AKOS015994615; Tox21_111242_1; AC-5266; API0003412; BCP9000933; CS-1823; DB12617; LP00745; SDCCGSBI-0050723.P004; HE 69; NSC 289637; MZB; Bredinin; IDI1_000948; SMP1_000195; NCGC00094087-02; NCGC00094087-03; NCGC00094087-04; NCGC00094087-05; NCGC00261430-01; HY-17470; LS-78195; Q571; SC-79295; BCP0726000318; SBI-0050723.P003; AB0017672; AB2000078; AX8140206; EU-0100745; FT-0630635; FT-0652030; ST24048110; A10597; A16794; D01392; AB00053323_12; AB00053323_13; 924M497; J-700185; Q6884708; SR-01000075989-1; SR-01000075989-4; 4-Carbamoyl-1-(beta-D-ribofuranosyl)-5-oxylatoimidazolium; 5-hydroxy-1-b-D-ribofuranosyl-1H-Imidazole-4-carboxamide; Bredinin, HE 69, NSC 289637, MZB, 50924-49-7; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-5-hydroxy-4-imidazolecarboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]-5-hydroxy-imidazole-4-carboxamide; 1-[(2R,3R,4S,5R)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-5-oxidanyl-imidazole-4-carboxamide; Bredinin|||HE-69|||NSC-289637|||1-[(2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxyimidazole-4-carboxamide; Mizoribine; Anhydro-4-carbamoyl-5-hydroxy-1-beta-D-ribofuranosyl-imidazolium hydroxide
Moclobemide 4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide; moclobemide; 71320-77-9; Aurorix; Manerix; Moclobemid; Moclamine; Moclaime; Moclobemidum; Moclamide; Moclobemida; Moclobemidum [INN-Latin]; Moclobemida [INN-Spanish]; p-Chloro-N-(2-morpholinoethyl)benzamide; Moclobemide (Ro 111163); 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-chloro-N-(2-morpholinoethyl)benzamide; 4-chloro-N-(2-morpholin-4-ylethyl)benzamide; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; Ro 11-1163; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; Moclobemide [USAN:INN:BAN]; GNF-PF-695; UNII-PJ0Y7AZB63; 4-chloro-N-[2-(4-morpholinyl)ethyl]benzamide; Ro-11-1163; HSDB 7180; Ro 11-1163/000; BENZAMIDE, 4-CHLORO-N-(2-(4-MORPHOLINYL)ETHYL)-; Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]-; BRN 0530974; PJ0Y7AZB63; CHEMBL86304; MLS000070549; Moclobamide; CHEBI:83531; YHXISWVBGDMDLQ-UHFFFAOYSA-N; NCGC00027930-02; NCGC00027930-04; SMR000012114; DSSTox_CID_20554; DSSTox_RID_79506; DSSTox_GSID_40554; Moclobemide [USAN:BAN:INN]; Auromid; Aurorix (TN); CAS-71320-77-9; SR-01000357772; CBMicro_048319; Moclobemide (USAN/INN); Ro111163; Moclamine (Salt/Mix); Opera_ID_225; Oprea1_256739; Oprea1_270122; SCHEMBL49708; MLS000759438; MLS001240195; MLS001424077; GTPL7428; DTXSID9040554; BDBM15613; AOB5012; HMS2051A16; HMS2096G07; HMS2232B20; HMS3262F09; HMS3371A01; HMS3393A16; HMS3657K05; HMS3713G07; BCP15783; HY-B0534; Moclobemide 1.0 mg/ml in Methanol; Tox21_110971; Tox21_113614; Tox21_500824; MFCD00865388; s3212; STK222240; ZINC19606670; AKOS003270184; Moclobemide, >=98% (HPLC), solid; Tox21_110971_1; CCG-100879; CS-2628; DB01171; LP00824; MCULE-5300106938; NC00129; Ro 111163; SDCCGSBI-0048213.P003; VA11315; NCGC00027930-03; NCGC00027930-05; NCGC00027930-07; NCGC00261509-01; AC-12467; AK607921; CPD000012114; H223; LS-26161; p-chloro-N-(2-morpholinoethyl)-benzamide; SAM001246614; SC-25719; BIM-0048213.P001; AB0012936; AB1009529; Ro-111163000; FT-0618228; M2733; ST45245423; SW197509-3; Ro-11-1163/000; A11885; D02561; 4-chloranyl-N-(2-morpholin-4-ylethyl)benzamide; AB00400932_12; 320M779; A837152; Q421934; SR-01000357772-1; SR-01000357772-4; Z32409934; (4-chlorophenyl)-N-(2-morpholin-4-ylethyl)carboxamide; BENZAMIDE,4-CHLORO-N-[2-(4-MORPHOLINYL)ETHYL]-; Ro11-1163; Ro 11-1163; Ro111163; Ro-111163; Ro 111163; MCL; Moclobemide; Aurorix
Monensin monensin; Monensic acid; monensin A; MonensiMonensinum; a17090-79-8; UNII-906O0YJ6ZP; A 3823A; Elancoban; Monelan; 906O0YJ6ZP; CHEBI:27617; GAOZTHIDHYLHMS-KEOBGNEYSA-N; Rumensin; Coban (as sodium salt); Monensinum [INN-Latin]; Monensina [INN-Spanish]; Rumensin (as sodium salt); Lilly 673140; HSDB 7031; ATCC 15413; EINECS 241-154-0; Rumensin 90; (2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-2-{(2S,2'R,3'S,5R,5'R)-2-ethyl-5'-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2H-pyran-2-yl]-3'-methyloctahydro-2,2'-bifuran-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl]-3-methoxy-2-methylpentanoic acid; NSC343257; Monensine; Monensin [USAN:USP:INN:BAN]; Monensin (INN); Stereoisomer of 2-(2-ethyloctahydro-3'-methyl-5'-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl)(2,2'-bifuran-5-yl))-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-1,6-dioxaspiro(4.5)decan-7-butanoic acid; Prestwick3_000748; SCHEMBL55367; BSPBio_000736; Elancoban [veterinary] (TN); BPBio1_000810; CHEMBL256105; DTXSID4048561; 1,6-Dioxaspiro(4.5)decane-7-butyric acid, 2-(5-ethyltetrahydro-5-(tetrahydro-3-methyl-5-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl)-2-furyl)-2-furyl)-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-; 1392-52-5; 2-[5-Ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxaspiro[4.5]decane-7-butyric acid; ZINC8143466; AKOS015964837; DB11430; E714; C06693; D08228; J-010665; Q3493048; SR-05000013702-2; BRD-K55375480-236-03-0; (2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-2-{(2S,2'R,3'S,5R,5'R)-2-Ethyl-5'-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl[2,2'-bioxolan]-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxy-2-methylpentanoic acid; (2S,3R,4S)-4-[(3S,5R,7S,8R,9S)-3-[(2R,5S)-5-ethyl-5-[(2R,3S,5R)-5-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-tetrahydropyran-2-yl]-3-methyl-tetrahydrofuran-2-yl]tetrahydrofuran-2-yl]-7-hydroxy-3,8-dimethyl-4,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methyl-pentanoic acid; monensin; monensin A; Elancoban; Monelan; 17090-79-8; Monensin, monosodium salt; Rumensin; Coban (Salt/Mix); Romensin (Salt/Mix); Rumensin (Salt/Mix); MLS006011801; SCHEMBL1143131; GAOZTHIDHYLHMS-UHFFFAOYSA-N; 1392-52-5; 2-[5-Ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxaspiro[4.5]decane-7-butyric acid; BCP30259; AKOS015842889; A-3823A; NSC-343257; 1,6-Dioxaspiro[4.5]decane-7-butyric acid, 2-[5-ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-; SMR004703486; FT-0601610; Monensic acid; Monensin A; Elancoban; Rumensin; 1, 2-[5-ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-, monosodium salt; 1,6-Dioxaspiro[4.5]decane-7-butanoic acid, 2-[2-ethyloctahydro-3'-methyl-5'-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl][2,2'-bifuran]-5-yl]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-; 2-[2-Ethyloctahydro-3'-methyl-5'-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl][2,2'-bifuran-5-yl]]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxapsiro[4.5]decan-7-butanoic acid; Stereoisomer of 2-[2-ethyloctahydro-3'-methyl-5'-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl][2,2'-bifuran-5-yl]]-9-hydroxy-.beta.-methoxy-.alpha.,.gamma.,2,8-tetramethyl-1,6-dioxaspiro[4.5]decan-7-butanoic acid; monensin; Rumensin; Elancoban; Monelan; monensin A; Q63393051; Coban (as sodium salt); Monensinum [INN-Latin]; Monensina [INN-Spanish]; Rumensin (as sodium salt); Lilly 673140; Monensin Monosodium Salt; Monensin-A-Sodium Complex; HSDB 7031; ATCC 15413; EINECS 241-154-0; C36H62O11; 17090-79-8; Monensin [USAN:BAN:INN]; SCHEMBL16931530; 1,6-Dioxaspiro(4.5)decane-7-butyric acid, 2-(5-ethyltetrahydro-5-(tetrahydro-3-methyl-5-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl)-2-furyl)-2-furyl)-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-; Stereoisomer of 2-(2-ethyloctahydro-3'-methyl-5'-(tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl)(2,2'-bifuran-5-yl))-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-1,6-dioxaspiro(4.5)decan-7-butanoic acid; LS-62394; Monensin - CASMI2016 Category 1 - Challenge 19; monensin; monensin A; 17090-79-8; C36H62O11; BSPBio_001277; CHEMBL504249; AKOS025311432; I022; 090M798; monensin; 17090-79-8; monensin; Prestwick0_000748; Prestwick1_000748; Prestwick2_000748; SPBio_002675; SCHEMBL16900229; BCBcMAP01_000001; SMP1_000198; monensin; ZINC8214427; monensin; monensin; A 3823A
Monensin sodium 2-[5-Ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyl-2H-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-beta-methoxy-alpha,gamma,2,8-tetramethyl-1,6-dioxaspiro[4.5]decane-7-butyric acid monosodium salt; Monensin sodium [USP]; AI3-29797
Monobactams Aztreonam; Carumonam
Monobenzone Hydroquinone monobenzyl ether; Monobenzone; 4-06-00-05728 (Beilstein Handbook Reference)
Morin 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; 2',4',5,7-Tetrahydroxyflavan-3-ol; Zlut prirodni 11; Bois d'arc [French]; UNII-8NFQ3F76WR; Zlut prirodni 11 [Czech]; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; NSC 19801; C.I. Natural Yellow 11 (VAN); C.I.Natural Yellow 8; NSC19801; EINECS 207-542-9; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; BRN 0327474; 8NFQ3F76WR; Flavone, 2',3,4',5,7-pentahydroxy-; CHEMBL28626; AI3-38057; MLS000069618; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; CHEBI:75092; 3,5 7 2 4-Pentahydroxyflavone; 2',4',5,7-Tetrahydroxyflavonol; 4H-1-Benzopyran-4-one, 2-2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-; NSC-19801; SMR000058259; M-8200; 2-[2,4-bis(oxidanyl)phenyl]-3,5,7-tris(oxidanyl)chromen-4-one; MORIN, REAG; SR-01000000157; CCRIS 8680; aluminium Ionophore I; Spectrum_001234; regid855692; Spectrum2_000715; Spectrum3_001941; Spectrum4_001924; Spectrum5_000737; Lopac0_000776; SCHEMBL19984; BSPBio_003541; GTPL411; KBioGR_002268; KBioSS_001714; 5-18-05-00492 (Beilstein Handbook Reference); MLS006012034; BIDD:ER0115; DivK1c_000958; SPECTRUM1502259; SPBio_000929; MEGxp0_001864; Morin, p.a., 97.0%; 2',3,5,7-Pentahydroxyflavone; DTXSID1022398; ACon1_000260; BDBM26658; cid_5281670; CTK5B4214; HMS502P20; KBio1_000958; KBio2_001714; KBio2_004282; KBio2_006850; KBio3_002824; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one; 2',4',5,7-Pentahydroxyflavone; 3,7,2',4'-Pentahydroxyflavone; NINDS_000958; YXOLAZRVSSWPPT-UHFFFAOYSA-N; 2',5,7-Tetrahydroxyflavan-3-ol; HMS1921P12; HMS3262K14; Flavone,3,4',5,7-pentahydroxy-; HY-N0621; ZINC3881558; ZX-AT022489; Tox21_500776; BBL036670; CCG-39036; LMPK12112517; MFCD00006826; s9110; SBB008853; STL559049; 2',3,4',5,7-pentahydroxy flavone; 2',3,4',5,7-Pentahydroxy-Flavone; AKOS001582671; LP00776; MCULE-2387347344; SDCCGMLS-0003296.P003; SDCCGSBI-0050754.P003; 2',4',5, 7-Tetrahydroxyflavan-3-ol; IDI1_000958; SMP1_000199; NCGC00015672-01; NCGC00015672-02; NCGC00015672-03; NCGC00015672-04; NCGC00015672-05; NCGC00015672-06; NCGC00015672-07; NCGC00015672-08; NCGC00015672-09; NCGC00015672-10; NCGC00015672-11; NCGC00015672-12; NCGC00015672-13; NCGC00015672-14; NCGC00022214-03; NCGC00022214-04; NCGC00022214-05; NCGC00022214-06; NCGC00022214-07; NCGC00178000-01; NCGC00178000-02; NCGC00261461-01; AK111274; LS-69029; NCI60_001647; SC-44859; AX8140380; DB-051497; 4CH-024478; CS-0009616; EU-0100776; FT-0628989; P0041; ST24039108; ST50308676; X1189; A-9317; C10105; M 4008; Q418224; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone; 91A9D69E-FAB0-45CD-90E5-DEEFBADE86C1; SR-01000000157-2; SR-01000000157-6; SR-01000000157-7; BRD-K11590034-001-01-0; aluminium Ionophore I, Selectophore(TM), function tested; 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-1-benzopyran-4-one; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one #; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 9CI; 4H-1-Benzopyran-4-one, 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-,monohydrate; 11128-85-1; Morin; C.I. 75660
Morphine (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; morphine; Morphia; Morphium; Morphina; Morphinum; Morphin; (-)-Morphine; Duromorph; DepoDur; Meconium; Morphinism; Moscontin; Ospalivina; MS Contin; l-Morphine; 57-27-2; Dulcontin; Morfina; Nepenthe; Roxanol; MORPHINE SULFATE; Infumorph; Dreamer; Morpho; Avinza; Hocus; Kadian; Unkie; Cube juice; Hard stuff; Oramorph SR; Statex SR; Ms Emma; Morphin [German]; Morfina [Italian]; Duramorph; Morphina [Italian]; M-Eslon; Morphine [BAN]; CCRIS 5762; Dolcontin; HSDB 2134; (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; UNII-76I7G6D29C; CHEBI:17303; CHEMBL70; EINECS 200-320-2; (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; DEA No. 9300; Morphine Anhydrate; 76I7G6D29C; Morphine (BAN); RMS; (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; methyl[?]diol; Aguettant; Dinamorf; Sevredol; Dimorf; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; (4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol; D-(-)-Morphine; Oramorph; (Morphine); Anhydrous morphine; Substitol (TN); MOR; (-)-(etorphine); (-)Morphine sulfate; Morfina Dosa (TN); SDZ202-250; NSC11441; SDZ 202-250; Epitope ID:116646; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-; SCHEMBL2997; BIDD:GT0147; GTPL1627; IDS-NM-009; DTXSID9023336; Morphine 0.1 mg/ml in Methanol; Morphine 1.0 mg/ml in Methanol; N02AA01; BQJCRHHNABKAKU-KBQPJGBKSA-N; ZINC3812983; BDBM50000092; AKOS015966554; DB00295; LS-91748; MOI; C01516; D08233; Q81225; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; UNII-1M5VY6ITRT component BQJCRHHNABKAKU-KBQPJGBKSA-N; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine); (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL; (5alpha,6beta)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; 3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester; 6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol; (1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraene-10,14-diol; (morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; HydroChloride; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; sulphate salt(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine)); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine sulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate); 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine); 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine); 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine); 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Morphine; 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol; Morphine; CCRIS 5762
Myricetin 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; myricetin; 529-44-2; Cannabiscetin; Myricetol; Myricitin; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; 3,3',4',5,5',7-Hexahydroxyflavone; 3,5,7,3',4',5'-Hexahydroxyflavone; UNII-76XC01FTOJ; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; 3,3',4,4',5',7-Hexahydro-2-phenyl-4H-chromen-4-one; NSC 407290; CCRIS 5838; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one; EINECS 208-463-2; NSC407290; CHEMBL164; NSC-407290; BRN 0332331; 76XC01FTOJ; CHEBI:18152; C15H10O8; FLAVONE, 3,3',4',5,5',7-HEXAHYDROXY-; MYC; AK111247; Q-100601; SMR001233193; SR-01000076005; HSDB 7682; 4gqr; Prestwick_342; Myricetin, 95%; Spectrum_001501; SpecPlus_000531; Prestwick0_000465; Prestwick1_000465; Prestwick2_000465; Prestwick3_000465; Spectrum4_001272; Spectrum5_000692; Lopac-M-6760; Myricetin (Cannabiscetin); Myricetin from Myrica cerifera leaf and bark; BIDD:PXR0079; Lopac0_000740; SCHEMBL19302; BSPBio_000570; KBioGR_001884; KBioSS_001981; MLS002153825; MLS006010718; BIDD:ER0142; DivK1c_006627; Myricetin, analytical standard; SPBio_002509; BPBio1_000628; MEGxp0_000357; DTXSID8022400; ACon1_000267; BDBM15236; cid_5281672; KBio1_001571; KBio2_001981; KBio2_004549; KBio2_007117; KS-00000GOF; 2o63; CHEBI: 18152; IKMDFBPHZNJCSN-UHFFFAOYSA-N; REGID_for_CID_5281672; HMS1569M12; HMS2096M12; HMS2231L04; HMS3262C22; HMS3656I05; BCP28295; Myricetin, >=96.0% (HPLC); Myricetin, >=96.0%, crystalline; TNP00286; ZINC3874317; Tox21_500740; BBL023468; BS0289; CM0160; GL5441; LMPK12110001; MFCD00006827; s2326; STL284709; 3,7,3',4',5'-Hexahydroxyflavone; AKOS015903103; AC-4533; CCG-204825; CS-6221; DB02375; KS-5268; LP00740; MCULE-6299186219; SDCCGSBI-0050718.P003; 3,3',4',5,5',7-hexOH-Flavone; Flavone,3',4',5,5',7-hexahydroxy-; NCGC00015697-01; NCGC00015697-02; NCGC00015697-03; NCGC00015697-04; NCGC00015697-05; NCGC00015697-06; NCGC00015697-07; NCGC00015697-08; NCGC00015697-09; NCGC00015697-10; NCGC00015697-11; NCGC00015697-12; NCGC00015697-13; NCGC00094083-01; NCGC00094083-02; NCGC00094083-03; NCGC00094083-04; NCGC00179517-01; NCGC00179517-02; NCGC00261425-01; 4CN-1085; CAS-529-44-2; HY-15097; LS-69005; NCI60_003870; ST057235; AB0149714; AX8140581; TR-018746; EU-0100740; FT-0672573; M2131; N1850; ST24041172; SW196616-2; C10107; M 6760; M-1214; S00115; 3,3',4',5,5',7-hexahydroxy-(8CI)- flavone; 529M442; A829320; Q951449; C07E0ED2-ABF6-4BD3-A2B2-A98CAEF20FD1; Myricetin, primary pharmaceutical reference standard; SR-01000076005-1; SR-01000076005-6; BRD-K43149758-001-04-5; 3,3′ ,4′ ,5,5′ ,7-Hexahydroxyflavone; Cannabiscetin; HSDB 7682; HSDB7682; HSDB-7682; 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-1-benzopyran-4-one; 3,5,7-Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one #; 3,5,7-tris(oxidanyl)-2-[3,4,5-tris(oxidanyl)phenyl]chromen-4-one; 4H-1-Benzopyran-4-one,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)- (9CI); 2-(3,4,5-TRIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-4H-1-BENZOPYRAN-4-ONE; 3,3',4',5,5',7-HEXAHYDROXYFLAVONE; MYRICETIN; CANNABISCETIN; Myricetin; 5-18-05-00670 (Beilstein Handbook Reference)
Myristic acid Tetradecanoic acid; Myristic acid; 4-02-00-01126 (Beilstein Handbook Reference)
Myxothiazol (2E,4R,5S,6E)-7-[2'-[(1S,2E,4E)-1,6-Dimethyl-2,4-heptadien-1-yl][2,4'-bithiazol]-4-yl]-3,5-dimethoxy-4-methyl-2,6-heptadienamide; Myxothiazol; Myxothiazol
N,N-Dimethyltryptamine N,N-Dimethyl-1H-indole-3-ethanamine; N,N-DIMETHYLTRYPTAMINE; DIMETHYLTRYPTAMINE; 61-50-7; 3-(2-Dimethylaminoethyl)indole; 2-(3-Indolyl)ethyldimethylamine; N,N-Dimethyl-1H-indole-3-ethylamine; 1H-Indole-3-ethanamine, N,N-dimethyl-; 2-(1H-Indol-3-yl)-N,N-dimethylethanamine; DMT (psychogenic); UNII-WUB601BHAA; 3-[2-(dimethylamino)ethyl]indole; EINECS 200-508-4; NSC 63795; WUB601BHAA; N,N-dimethyl-1H-Indole-3-ethanamine; BRN 0138259; CHEMBL12420; DEA No. 7435; CHEBI:28969; (2-Indol-3-ylethyl)dimethylamine; DMULVCHRPCFFGV-UHFFFAOYSA-N; 1H-Indole-3-ethanamine,N,N-dimethyl-; Indole, 3-(2-(dimethylamino)ethyl)-; Indole, 3-[2-(dimethylamino)ethyl]-; D-5500; [2-(1H-INDOL-3-YL)-ETHYL]-DIMETHYL-AMINE; (psychogenic); HSDB 8017; Indolalkylamine der; Dimethyltryptamine(DMT); (N,N)-Dimethyltryptamine; GTPL141; 3-(dimethylaminoethyl)-indole; SCHEMBL335710; 2-(1H-INDOL-3-YL)-N,N-DIMETHYL-ETHANAMINE; CTK5B3344; DTXSID60110053; N,N-Dimethyltryptamine, free base; ZINC897457; NSC63795; WLN: T56 BMJ D2N1&1; 3-(2-(dimethylamino)ethyl)-Indole; BDBM50026868; FCH838678; MFCD00055989; NSC-63795; STK370594; 3-[2- (dimethylamino)ethyl]-Indole; AKOS005446117; DB01488; MB00483; [2-(1H-indol-3-yl)ethyl]dimethylamine; 3-(2-DIMETHYLAMINOETHYL) INDOLE; 2-(1H-indol-3-yl)-ethyl-dimethyl-amine; AS-47089; LS-82930; N,N-Dimethyltryptamine, >=97% (HPLC); 2-(1H-indol-3-yl)-N,N-dimethylethylamine; 1H-INDOLE-3-ETHANAMINE,N,N-DIMETHYL; FT-0667348; N,N-dimethyl-1H-Indole-3-ethanamine (9CI); 2-(1H-Indol-3-yl)-N,N-dimethylethanamine #; C08302; 1H-Indole-3-ethanamine, N,N-dimethyl- (9CI); 2-(1H-Indol-3-yl)-N,N-dimethylethan-1-amine; 061D507; L001288; Q407217; 2-(1H-indol-3-yl)-N,N-dimethylethanamine (ACD/Name 4.0); N-(2-(1H-indol-3-yl)ethyl)-N,N-dimethylamine (ACD/Name 4.0); N,N-Dimethyltryptamine (DMT) solution, 1.0 mg/mL in methanol, certified reference material; InChI=1/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H; N,N-Dimethyltryptamine; 5-22-10-00048 (Beilstein Handbook Reference)
N-(2-(4-Bromocinnamylamino)ethyl)-5-isoquinolinesulphonamide N-[2-[[3-(4-Bromophenyl)-2-propen-1-yl]amino]ethyl]-5-isoquinolinesulfonamide; h-89; 127243-85-0; H 89; C20H20BrN3O2S; UNII-M876330O56; CHEMBL104264; N-(2-(4-Bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; M876330O56; N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE; 5-Isoquinolinesulfonamide, N-(2-((3-(4-bromophenyl)-2-propenyl)amino)ethyl)-; N-(2-((3-(4-Bromophenyl)-2-propenyl)amino)ehtyl)-5-isoquinolinesulfonamide dihydrochloride; N-(2-{[(2E)-3-(4-bromophenyl)prop-2-en-1-yl]amino}ethyl)isoquinoline-5-sulfonamide; H89; H-89, Dihydrochloride; N-[2-[p-Bromocinnamylamino]ethyl]-5-isoquinolinesulfonmide; (E)-N-(2-((3-(4-bromophenyl)allyl)amino)ethyl)isoquinoline-5-sulfonamide; N-[2-[[3-(4-Bromophenyl)-2-propen-1-yl]amino]ethyl]-5-isoquinolinesulfonamide; N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE; N-[2-(4-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide; 1ydt; N-(2-{[3-(4-bromophenyl)prop-2-en-1-yl]amino}ethyl)isoquinoline-5-sulfonamide; N-[2-[[(E)-3-(4-bromophenyl)prop-2-enyl]amino]ethyl]isoquinoline-5-sulfonamide; H89 dihydrochloride/; N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride; BiomolKI_000035; BiomolKI2_000043; H-89 (hydrochloride salt); N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide; Lopac0_000140; BSPBio_001107; SCHEMBL123495; Protein kinase inhibitor H-89; BMK1-D11; GTPL5983; BDBM15211; BRD7647; BCPP000214; HMS1362G09; HMS1792G09; HMS1990G09; HMS3403G09; BCP02706; BRD-7647; EX-A2432; ZINC2043204; 3896AH; ABP000806; EI-196; AKOS025394289; BCP9000757; CCG-100639; CS-3386; DB07995; LS40144; SB19596; IDI1_002139; NCGC00162073-01; NCGC00162073-02; NCGC00162073-03; NCGC00162073-04; NCGC00162073-13; AC-27757; AS-73687; HY-15979; LS-172674; RT-013181; A11935; S-7693; Q5627831; BRD-K27737647-001-04-2; BRD-K27737647-300-01-4; N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide; (E)-N-(2-(3-(4-bromophenyl)allylamino)ethyl)isoquinoline-5-sulfonamide; N-[2-[[(E)-3-(4-bromophenyl)allyl]amino]ethyl]isoquinoline-5-sulfonamide; N-[2-[3-(4-bromophenyl)prop-2-enylamino]ethyl]isoquinoline-5-sulfonamide; 5-Isoquinolinesulfonamide, N-[2-[[3-(4-bromophenyl)-2-propen-1-yl]amino]ethyl]-; N-(2-(4-Bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; H-89
N-(3-Methylbut-2-EN-1-YL)-9H-purin-6-amine N-(3-Methyl-2-butenyl)-1H-purin-6-amine; 2365-40-4; Isopentenyladenine; N6-Isopentenyladenine; IPADE; N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE; 6-(gamma,gamma-Dimethylallylamino)purine; Isopentenyl adenine; N6-(2-Isopentenyl)adenine; N6-Dimethylallyladenine; Dimethylallyladenine; Enadenine; N6-(2-Isopentenyl)-adenine; N6-(delta2-Isopentenyl)adenine; N-(3-Methyl-2-butenyl)adenine; N6-(3-Methyl-2-butenyl)adenine; N6-(delta2-Isopentenyl)-adenine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-; N6-(delta 2-Isopentenyl)-adenine; N-(3-methylbut-2-enyl)-7H-purin-6-amine; N(6)-(delta(2)-Isopentenyl)adenine; N(6)-dimethylallyladenine; isopentenyl-adenine; Adenine, N-(3-methyl-2-butenyl)-; 6-((3-Methyl-2-butenyl)amino)purine; NSC 106958; UNII-V500BB256Z; N-(delta2-Isopentenyl)adenine; N6-(3-Methylbut-2-enyl)adenine; N-(3-Methyl-2-butenyl)-1H-purin-6-amine; N6-(delta2-Isopentenyl)aminopurine; N-(gamma,gamma-Dimethylallyl)adenine; NSC106958; 2ip; CHEBI:17660; HYVABZIGRDEKCD-UHFFFAOYSA-N; N-(.DELTA.2-Isopentenyl)adenine; V500BB256Z; N6-(.DELTA.2-Isopentenyl)adenine; 6-(|A,|A-Dimethylallylamino)purine; (3-methylbut-2-enyl)purin-6-ylamine; NSC-106958; 6-[(3-Methyl-2-butenyl)amino]purine; N6-(.DELTA.2-Isopentenyl)aminopurine; 6-(3-methyl-2-buten-1-ylamino)purine; 6-(3,3-DIMETHYLALLYLAMINO)PURINE; N-(.gamma.,.gamma.-Dimethylallyl)adenine; 6-(.gamma.,.gamma.-Dimethylallylamino)purine; D-4760; 2exm; n-isopentenyladenine; N-(3-methylbut-2-enyl)-9H-purin-6-amine; NCIStruc1_000935; NCIStruc2_000921; TimTec1_003281; N6-Delta2-isopentenyladenine; Oprea1_344117; SCHEMBL459276; BID525; CHEMBL476189; CTK8G1492; ZINC32351; DTXSID10178325; N-6-(3,3-Dimethylallyl)adenine; ZX-AFC000343; HMS1543F03; N(6)-(Delta2-isopentenyl)adenine; N-6-(delta2-Isopentenyl)-adenine; N6-.DELTA.2-Isopentenyl)adenine; EBD28940; CCG-38046; CI-027; NCGC00014084; NCI106958; s5690; AKOS005257639; AKOS015914857; ACM2365404; DB08768; MCULE-6781114249; NCGC00014084-02; NCGC00097193-01; 3-methylbut-2-enyl(7H-purin-6-yl)amine; AC-15608; AK163607; AS-17517; NCI60_000165; SC-18768; ST044513; 6-[(3-methylbut-2-en-1-yl)amino]purine; N(6)-(.DELTA.2-Isopentenyl)aminopurine; AX8017021; HY-112103; LS-184209; N-(3-methyl-2-butenyl)-9H-purin-6-amine; Adenine, N-(3-methyl-2-butenyl)- (8CI); CS-0043352; FT-0629731; ST24048354; V0538; C04083; N-(3-Methyl-2-butenyl)-1H-purin-6-amine #; N-(3-methylbut-2-en-1-yl)-7H-purin-6-amine; 365I404; A816825; Q569031; (3-methyl-but-2-enyl)-(7(9)H-purin-6-yl)-amine; 1H-Purin-6-amine, N-(3-methyl-2-butenyl)- (9CI); BRD-K62158429-001-01-7; 6-(gamma,gamma-Dimethylallylamino)purine, BioReagent, plant cell culture tested, >=90%; 6-(gamma,gamma-Dimethylallylamino)purine, BioReagent, plant cell culture tested, >=98.5%; 6-(gamma,gamma-Dimethylallylamino)purine, BioReagent, plant cell culture tested, 1 mg/mL; 6-(gamma,gamma-Dimethylallylamino)purine, Vetec(TM) reagent grade, >=98.5%; N(6)-(delta(2)-Isopentenyl)adenine; 2ip
N-Acetylsulphanilyl chloride 4-(Acetylamino)benzenesulfonyl chloride; p-Acetamidobenzenesulfonyl chloride
N-Allylaniline N-2-Propen-1-ylbenzenamine; N-Allylaniline; AI3-10028
N-Butylbenzenesulphonamide N-BUTYLBENZENESULFONAMIDE; 3622-84-2; Benzenesulfonamide, N-butyl-; Plastomoll BMB; N-n-Butylbenzenesulfonamide; Dellatol BBS; N-BUTYL-BENZENESULFONAMIDE; N-Butylbenzenesulphonamide; Plasthall BSA; Cetamoll BMB; Benzenesulfonic acid butyl amide; N-Butylbenzene sulfonamide; Uniplex 214; BM 4 (sulfonamide); N-(n-Butyl)benzenesulfonamide; NSC 3536; UNII-YO7UAW6717; EINECS 222-823-6; BRN 2725965; AI3-08011; YO7UAW6717; DTXSID7027540; CHEBI:44237; IPRJXAGUEGOFGG-UHFFFAOYSA-N; butyl(phenylsulfonyl)amine; DSSTox_CID_7540; DSSTox_RID_78496; DSSTox_GSID_27540; NBB; CAS-3622-84-2; N-Benzenesulfonylbutylamine; N-n-Butyl benzenesulfonamide; MFCD00025024; 3cz1; ACMC-1CJLM; n-butyl benzenesulfonamide; N- butylbenzenesulfonamide; EC 222-823-6; Cambridge id 5182395; SCHEMBL51729; 4-11-00-00051 (Beilstein Handbook Reference); KSC490A3B; CHEMBL479880; N-Butylbenzenesulfonamide, 99%; CTK3J0030; NSC3536; 3d78; HMS3604D04; NSC-3536; ZINC1666831; Tox21_201692; Tox21_303184; ANW-28376; SBB008484; AKOS000120870; ANGC-3622-84-2; DB02055; MCULE-9258708920; MS-7234; RTR-014879; TRA0069604; KS-0000109N; N-n-Butylamide of Benzenesulphonic Acid; NCGC00164214-01; NCGC00164214-02; NCGC00256957-01; NCGC00259241-01; AC-12448; LS-31335; M742; DB-080953; TR-014879; B0716; FT-0653652; ST24031394; ST50409358; AB00037309-01; AB00037309-02; A823172; W-106634; Q14853448; Z45516915; F1113-0008; benzenesulfonamide, n-butyl-; n-butylbenzenesulfonamide; n-butylbenzenesulphonamide; benzenesulfonamide, n-butyl- n-butylbenzenesulfonamide n-butylbenzenesulphonamide; InChI=1/C10H15NO2S/c1-2-3-9-11-14(12,13)10-7-5-4-6-8-10/h4-8,11H,2-3,9H2,1H; 4-11-00-00051 (Beilstein Handbook Reference)
N-Ethylmaleimide 1-Ethyl-1H-pyrrole-2,5-dione; N-ethylmaleimide; 128-53-0; 1-Ethyl-1H-pyrrole-2,5-dione; ethylmaleimide; 1H-pyrrole-2,5-dione, 1-ethyl-; maleimide, N-ethyl-; NEM; maleic acid N-ethylimide; USAF B-121; 1-ethylpyrrole-2,5-dione; UNII-O3C74ACM9V; NSC 7638; EINECS 204-892-4; MFCD00005509; BRN 0112448; CHEMBL8211; O3C74ACM9V; AI3-50085; CHEBI:44485; HDFGOPSGAURCEO-UHFFFAOYSA-N; N-Ethylmaleimide, 99+%; 25668-22-8; n-ethylmaleimide (nem); N-EM; Lopac-E-3876; ACMC-209bf8; 1-ethylazoline-2,5-dione; WLN: T5VNVJ B2; 1H-Pyrrole-2, 1-ethyl-; Lopac0_000492; SCHEMBL19666; KBioGR_002548; KBioSS_002557; 5-21-10-00006 (Beilstein Handbook Reference); Maleimide, N-ethyl- (8CI); GTPL5335; SCHEMBL9359266; DTXSID1059573; CTK1A6181; KBio2_002548; KBio2_005116; KBio2_007684; KBio3_003026; KS-00000GSO; NSC7638; cMAP_000078; Bio1_000439; Bio1_000928; Bio1_001417; HMS3261D05; ZINC901367; 1-Ethyl-1H-Pyrrole-2, 5-dione; 1-ethyl-3-pyrroline-2,5-quinone; EBD21453; HY-D0843; NSC-7638; NSC92547; 1-Ethyl-1H-pyrrole-2,5-dione #; Tox21_500492; 7671AF; ANW-19074; BDBM50220832; GEO-01358; HSCI1_000382; NSC-92547; PI-149; s3692; STK802307; AKOS000249392; AKOS025244114; CCG-204583; DB02967; FS-4064; LP00492; LS41520; MCULE-9216989340; SDCCGSBI-0050476.P003; TRA0003746; NCGC00015415-01; NCGC00015415-02; NCGC00015415-03; NCGC00015415-04; NCGC00093895-01; NCGC00093895-02; NCGC00261177-01; AK-47781; 1-ETHYL-1H-PYRROLE-2,5-DIONENEM; DB-041899; LS-136944; TC-107819; TR-004010; 1-ethyl-2,5-dihydro-1H-pyrrole-2,5-dione; CS-0014814; E0136; EU-0100492; FT-0631750; N-Ethylmaleimide, BioXtra, >=98% (HPLC); ST24037988; ST51037241; C02441; E 3876; E-8100; N-Ethylmaleimide, crystalline, >=98% (HPLC); N-Ethylmaleimide, BioUltra, >=99.0% (HPLC); Q292393; SR-01000075860; N-Ethylmaleimide, purum p.a., >=99.0% (HPLC); SR-01000075860-1; BRD-K98297262-001-01-1; 4D028806-9A8A-4D25-B355-AEFDEC5AD901; F0001-0396; InChI=1/C6H7NO2/c1-2-7-5(8)3-4-6(7)9/h3-4H,2H2,1H; Ethylmaleimide; 5-21-10-00006 (Beilstein Handbook Reference)
Nadolol 5-[3-[(1,1-Dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-naphthalenediol; Nadolol; Anabet
Nafarelin 6-[3-(2-Naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine); Nafarelin; LHRH, Ala(2-naphthyl)(6)-
Naled Phosphoric acid 1,2-dibromo-2,2-dichloroethyl dimethyl ester; Naled; AI3-24988
Nalidixic acid 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; Nalidixic acid; 5-25-07-00384 (Beilstein Handbook Reference)
Naloxone (5 alpha)-4,5-Epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one; Naloxone; l-N-Allyl-7,8-dihydro-14-hydroxynormorphinone
Naltrexone (5.alpha.)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one; Naltrexone; BRN 3596648
Naproxen (alphaS)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Naproxen; RS-3540